Chikungunya virus is spread by infected mosquitos. It can cause fever, headache, muscle pain, fatigue and joint pain. According to the Center for Disease Control, outbreaks have occurred in Africa, Asia, Europe, the Indian and Pacific Oceans and as of September 2020, there have been more than 3 million reported cases in the Americas.
AMR Norfolk is developing an investigational vaccine to prevent CHIKV infection in the general population living in endemic regions as well as to serve as a prophylactic measure for travelers who are going to affected areas. Currently, there is no FDA-approved vaccine to prevent or medicine to treat chikungunya.
- Age 18 years or older
- Are in good or stable health (you may have underlying medical conditions, if your symptoms and signs are stable and well-controlled).
- Willing to adhere to the time and compliance requirements. Participation in this study is voluntary, and you can leave the study at any time.
If Qualified and you participate you will receive:
- All study-related medical exams, lab tests, investigational medication or placebo at no cost.
- Compensation for time and travel.
- Insurance is not required.
Take the next step, call us at (757) 627-6798 and ask for the enrollment team, better yet, fill out the brief contact form, and we will call you! This will help us determine if you meet some of the initial criteria necessary to participate. We will contact you within 48 hours to follow-up and clarify any questions that you, or we, may have. The information you provide is entered in our secure, password protected database which can only be accessed by authorized AMR Norfolk personnel, unless given your permission or except as required by law. Provided information will only be used to contact you to tell you more about this and any future study. Your contact information will remain within our database indefinitely unless otherwise requested.